Connect
MJA
MJA

Time trends in cancer incidence and mortality

Bruce K Armstrong
Med J Aust 2013; 199 (9): . || doi: 10.5694/mja13.11247
Published online: 4 November 2013

What do they tell us about cancer control in Australia?

There have been some spectacular trends, both good and bad, in cancer incidence and mortality in Australia over the past three decades. Using data from the Australian Institute of Health and Welfare (AIHW),1 the annual average percentage change in incidence and mortality of the most common cancers in Australia can be calculated for this period, as shown in the Box. Perhaps the most notable trends are annual 5%–6% rises in the incidence of hepatic and prostatic cancers and 4%–5% falls in mortality from Hodgkin lymphoma and cervical and testicular cancers. These examples reflect the annual trends in the rates of all cancers: increasing incidence of 0.7% (95% CI, 0.5%–0.9%) and falling mortality of 1.4% (95% CI, 1.2%–1.5%).


  • 1 The Sax Institute, Sydney, NSW.
  • 2 Sydney School of Public Health, University of Sydney, Sydney, NSW.



Acknowledgements: 

Chris Goumas did the statistical analysis of annual percentage changes in cancer rates.

Competing interests:

No relevant disclosures.

  • 1. Australian Institute of Health and Welfare. Australian cancer incidence and mortality (ACIM) books. Canberra: AIHW, 2012. http://www.aihw.gov.au/acim-books (accessed Oct 2013).
  • 2. Amin J, O’Connell D, Bartlett M, et al. Liver cancer and hepatitis B and C in New South Wales, 1990–2002: a linkage study. Aust N Z J Public Health 2007; 31: 475-482.
  • 3. Aminisani N, Armstrong BK, Egger S, Canfell K. Impact of organised cervical screening on cervical cancer incidence and mortality in migrant women in Australia. BMC Cancer 2012; 12: 491.
  • 4. Smith DP, Supramaniam R, Marshall VR, Armstrong BK. Prostate cancer and prostate-specific antigen testing in New South Wales. Med J Aust 2008; 189: 315-318. <MJA full text>
  • 5. Kahn C, Simonella L, Sywak M, et al. Pathways to the diagnosis of thyroid cancer in New South Wales: a population-based cross-sectional study. Cancer Causes Control 2012; 23: 35-44.
  • 6. Marcus R, Hagenbeek A. The therapeutic use of rituximab in non-Hodgkin’s lymphoma. Eur J Haematol Suppl 2007; (67): 5-14.
  • 7. Rutten H, den Dulk M, Lemmens V, et al. Survival of elderly rectal cancer patients not improved: analysis of population based data on the impact of TME surgery. Eur J Cancer 2007; 43: 2295-2300.
  • 8. Australian Institute of Health and Welfare. Health system expenditure on disease and injury in Australia, 2004-05. Canberra: AIHW, 2010. (AIHW Cat. No. HSE 87; Health and Welfare Expenditure Series No. 36.) http://www.aihw.gov.au/publication-detail/?id=6442468349 (accessed Sep 2013).
  • 9. Roder DM. The epidemiology of gastric cancer. Gastric Cancer 2002; 5 Suppl 1: 5-11.
  • 10. Thein HH, Walter SR, Gidding HF, et al. Trends in incidence of hepatocellular carcinoma after diagnosis of hepatitis B or C infection: a population-based cohort study, 1992-2007. J Viral Hepat 2011; 18: e232-e241.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.